ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,381.35
0.33%
Dow Jones
39,308.69
0.65%
Gold vs US Dollar
2,333.02
1.08%
Brent Oil
83.405
-0.19%
Bitcoin
62,108.61
1.51%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Minerva Neurosciences Inc (NERV)

  7. Minerva Neurosciences Inc (NERV) News

Minerva Neurosciences (NERV)

Minerva Neurosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NERV
DateTimeSourceHeadlineSymbolCompany
01/05/202412:30GlobeNewswire Inc.Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
27/02/202413:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
27/02/202413:00GlobeNewswire Inc.Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
22/02/202412:00GlobeNewswire Inc.Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
22/02/202411:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NERVMinerva Neurosciences Inc
07/11/202312:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
07/11/202312:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NERVMinerva Neurosciences Inc
05/10/202321:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
05/10/202321:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
29/09/202313:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
29/09/202313:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
28/09/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
15/08/202314:28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NERVMinerva Neurosciences Inc
15/08/202314:26Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NERVMinerva Neurosciences Inc
15/08/202314:25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NERVMinerva Neurosciences Inc
10/08/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NERVMinerva Neurosciences Inc
09/08/202322:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NERVMinerva Neurosciences Inc
04/08/202313:07Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NERVMinerva Neurosciences Inc
01/08/202312:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
01/08/202312:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NERVMinerva Neurosciences Inc
07/07/202321:18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NERVMinerva Neurosciences Inc
03/07/202321:04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NERVMinerva Neurosciences Inc
28/06/202313:38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NERVMinerva Neurosciences Inc
28/06/202313:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
28/06/202313:30GlobeNewswire Inc.Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketNASDAQ:NERVMinerva Neurosciences Inc
20/06/202313:41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NERVMinerva Neurosciences Inc
15/05/202312:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
15/05/202312:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NERVMinerva Neurosciences Inc
10/05/202313:00GlobeNewswire Inc.Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
08/05/202313:30GlobeNewswire Inc.Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023NASDAQ:NERVMinerva Neurosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NERV

Your Recent History

LSE
TERN
Tern
LSE
POS
Plexus
LSE
SCE
Surface Transforms
LSE
KEFI
Kefi Gold And Copper
LSE
BIRD
Blackbird
LSE
GOLD
LSE
SYME
Supply@me Capital
LSE
ITV
Itv
LSE
PET
Petrel Resources
LSE
AGL
Angle
LSE
GCM
Gcm Resources
LSE
BOO
Boohoo
LSE
GWMO
Great Western Mining
LSE
GDR
Genedrive
LSE
AAU
Ariana Resources
LSE
SAR
Sareum
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved